Given the extensive research and development that has already been conducted on Akt inhibitors for cancers, their pharmacokinetics, safety profiles, and molecular interactions are well understood, making them strong candidates for repurposing in IPF (Table 1) (57, 77). Here, AKT1 is linked to idiopathic pulmonary fibrosis.